ACADIA Pharmaceuticals Inc.

ACAD Healthcare Biotechnology

ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024. In the quarter to June 2026, revenue grew 16.4%, EPS grew 12.5% and free cash flow grew 50.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

19.12 0.59 −2.99%
Market cap
$3.4B
P/E
8.5×
Fwd P/E
55.6×
Dividend yield
—
F-score
6/9
Altman Z
7.90
Beneish M
−0.89
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
11.51 13.49 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Piotroski F-Score
6 4 5 4 4 4 6 6 5 3
Altman Z-Score
7.90 3.41 6.38 3.00 10.59 29.17 42.35 16.22 39.37 44.08
P/S ratio
4.20 3.17 6.96 5.10 7.74 19.04 18.57 9.15 29.87 192.33
P/FCF ratio
0.00 25.96 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
3.79 (0.05) (6.64) (9.19) (3.21) (1.37) 5.27 1.95 (2.80) 9.95
Beneish M-Score
(0.89) (2.27) (2.45) (3.42) (2.32) (2.69) (2.44) (2.50) 1.51 250.24
P/Operating CF
(92.28) 75.31 59.21 (110.62) (162.02) (305.98) (211.98) (52.38) (124.79) (54.47)
P/B ratio
3.66 4.15 11.71 6.59 6.93 13.41 9.01 4.27 11.13 6.43
Price to Tangible BV
4.02 4.96 13.80 6.60 6.93 13.44 9.04 4.31 11.31 6.52
EV/Sales
3.43 2.39 6.36 4.30 6.66 17.61 16.52 7.03 27.14 161.81
EV/EBITDA
33.08 9.63 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
33.48 14.49 276.42 (19.49) (25.67) (57.13) (37.05) (9.40) (15.57) (13.46)
EV/FCF
(39.55) 19.51 (197.73) (19.30) (25.44) (54.11) (36.78) (9.28) (15.51) (13.36)
Quick Ratio
3.49 2.18 2.13 3.82 6.10 6.44 9.83 8.42 7.34 12.59
Current Ratio
3.83 2.38 2.42 4.04 6.43 6.77 10.16 8.83 7.62 12.87
Net Debt/EBITDA
(7.37) (3.18) 5.82 1.86 3.16 2.24 2.82 1.93 1.18 1.95
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.03%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
0.78 0.99 1.09 0.80 0.65 0.56 0.51 0.48 0.26 0.04
Operating CF/Net income
0.28 0.70 (0.27) 0.53 0.75 0.48 0.64 0.68 0.75 0.77
Capex/Depreciation
(0.74) (0.08) 20.22 0.00 (0.20) (1.72) 1.33 (0.87) (0.34) (4.96)
ROE
39.89% 38.89% (14.73%) (45.89%) (28.75%) (42.47%) (39.93%) (60.22%) (67.80%) (75.58%)
ROA
28.42% 23.39% (9.17%) (33.54%) (22.64%) (35.97%) (35.55%) (53.03%) (61.21%) (69.32%)
ROIC
16.07% 0.00% 0.00% 0.00% (527.66%) 0.00% (9,032.28%) (2,782.02%) 0.00% 0.00%
Return on Tangible Assets
49.34% 41.35% (16.72%) (55.62%) (31.69%) (45.36%) (34.16%) (52.19%) (88.47%) (53.38%)
Average Days of Receivables
50.49 39.90 51.43 44.51 49.26 41.55 40.77 45.32 53.86 150.37
Research and Development Expense of Revenue
30.69% 31.66% 48.40% 69.91% 49.45% 72.24% 70.89% 83.63% 119.45% 572.87%
Selling, General and Administrative Expense of Revenue
51.23% 50.99% 55.97% 71.36% 81.80% 87.98% 96.04% 118.74% 204.21% 1,075.85%
Intangible Assets out of Total Assets
0.07 0.10 0.09 0.00 0.00 0.00 0.00 0.01 0.01 0.01
Share Based Compensation of Revenue
4.87% 7.00% 9.14% 13.19% 13.14% 19.11% 24.26% 36.44% 60.47% 318.88%
Graham Net Nets
0.16 0.16 0.06 0.12 0.12 0.07 0.11 0.23 0.09 0.15
Graham Number
19.51 11.63 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
8.69% 7.41% (1.24%) (8.21%) (4.50%) (3.37%) (3.74%) (12.06%) (7.72%) (8.13%)
Free Cash Flow Yield
(2.07%) 3.85% (0.46%) (4.36%) (3.38%) (1.71%) (2.42%) (8.28%) (5.86%) (6.30%)
Revenue per Share
6.36 5.78 4.43 3.20 3.02 2.81 2.30 1.77 1.02 0.15
Operating CF per Share
0.65 0.95 0.10 (0.71) (0.78) (0.87) (1.03) (1.32) (1.78) (1.80)
Capex per Share
(0.03) 0.00 (0.24) 0.00 (0.01) (0.05) (0.01) (0.02) (0.01) (0.08)
Free Cash Flow per Share
0.62 0.95 (0.14) (0.71) (0.79) (0.91) (1.03) (1.34) (1.78) (1.88)
Cash per Share
4.87 4.56 2.68 2.58 3.24 4.02 4.74 3.74 2.78 4.57
Shareholders Equity per Share
7.29 4.42 2.64 2.48 3.37 3.99 4.75 3.78 2.73 4.47
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
7.29 4.42 2.64 2.48 3.37 3.99 4.75 3.78 2.73 4.47
Free Cash Flow
105.15 157.20 (23.35) (114.03) (126.78) (143.75) (152.26) (169.57) (218.57) (217.91)
Working Capital
785.00 543.45 361.87 382.31 521.76 611.65 685.42 466.54 324.45 505.31
Capital Expenditures
(4.69) (0.52) (40.05) — (1.12) (7.59) (1.13) (2.10) (0.81) (9.51)
Net Current Asset Value
725.31 483.36 298.92 320.54 458.60 562.01 676.20 464.98 324.26 505.16
EV/EBIT
35.08 9.90 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.00 0.06 0.00 0.00 0.02 0.00 0.01 0.01 0.55
Price to Operating Income
42.90 13.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.84 1.56 (0.43) (0.12) 0.71 0.48 (0.27) 0.73 0.91 0.62
Cash ROIC
5.14% 10.56% (2.68%) (13.95%) (11.94%) (11.42%) (10.90%) (17.80%) (32.30%) (20.80%)
Accounts Receivable Turnover
8.47 9.25 8.78 8.06 8.37 10.02 10.33 9.68 9.77 3.95
Accounts Payable Turnover
6.57 4.85 2.75 1.04 2.49 1.30 2.18 2.07 1.43 1.10
Inventory Turnover
3.14 2.83 1.96 1.40 2.18 1.27 2.18 2.66 1.93 0.65
Average Days of Payables
44.72 72.21 153.78 457.63 131.12 303.59 232.37 93.40 353.30 464.35
Days of Inventory on Hand
142.19 97.89 313.99 238.26 150.28 346.09 204.03 120.03 211.03 495.57
Average Receivables
126.46 103.52 82.72 64.21 57.81 44.08 32.83 23.11 12.79 4.39
Average Payables
13.55 16.87 15.14 9.81 7.68 7.86 5.19 5.98 6.35 2.79
Average Inventory
28.31 28.88 21.23 7.26 8.78 8.01 5.21 4.66 4.71 4.71
Average Assets
1,375.98 968.36 668.38 643.97 741.37 782.90 661.69 462.35 472.83 391.52
Average Common Equity
980.09 582.27 416.08 470.65 583.95 663.07 589.11 407.18 426.85 359.09

Fold the line items

Columns are period end dates